Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)
|MDS||Procedure: Allogeneic Hematopoietic Cell Transplant Procedure: Hypomethylating Therapy / Best Supportive Care Drug: Reduced Intensity Conditioning||Phase 2|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||A Multi-Center Biologic Assignment Trial Comparing Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients w/Intermediate-2 & High Risk Myelodysplastic Syndrome (BMT CTN #1102)|
- Overall survival probabilities [ Time Frame: 3 years ]
- Leukemia-free survival (LFS) [ Time Frame: 3 years ]
- QOL measures [ Time Frame: 3 years ]
|Actual Study Start Date:||December 2013|
|Estimated Study Completion Date:||June 2021|
|Estimated Primary Completion Date:||June 2020 (Final data collection date for primary outcome measure)|
Active Comparator: Transplant
Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT)
Procedure: Allogeneic Hematopoietic Cell Transplant
Bone marrow or peripheral blood stem cell transplant.
Other Name: RIC alloHCTDrug: Reduced Intensity Conditioning
The specific transplant treatment regimen will be at the discretion of the treating physician.
Other Name: RIC
Active Comparator: Non-Transplant
Hypomethylating Therapy / Best Supportive Care
Procedure: Hypomethylating Therapy / Best Supportive Care
The specific non-transplant treatment regimen will be at the discretion of the treating physician.
Other Name: Non-transplant
Background: MDS is a clonal disorder of hematopoietic precursors and stem cells, which may evolve to a terminal phase resembling acute leukemia. A subject of clinical urgency for researchers, clinicians, patients, and health care underwriters such as Medicare, is the role of allogeneic hematopoietic cell transplantation (alloHCT) in the treatment of older patients with higher risk myelodysplastic syndromes (MDS). The use of reduced intensity conditioning (RIC) regimens has extended HCT to the care of older patients with acute myelogenous leukemia (AML) and lymphoma and a number of retrospective and phase II trials for patients with MDS now show the curative potential of RIC alloHCT in selected patients.
This protocol is designed to evaluate the relative benefits of RIC alloHCT compared to non-transplant therapies focusing on overall survival. This will be done by having patients biologically assigned to the alloHCT arm or the hypomethylating therapy/best supportive care arm and following them for survival at 3 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02016781
Show 36 Study Locations
|Study Director:||Mary Horowitz, MD, MS||Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin|